Trial Profile
A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2017
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Adenosquamous carcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PAN-01
- 07 Jun 2016 Primary endpoint has not been met. (Overall survival), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2015 The follow-up phase is ongoing and a final analysis will be conducted in July 2015, according to the ASCO 2015 abstract.